title: Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
authors.affiliation: Department of Dermatology, Kyoto University Graduate School of Medicine, Sho-goin Kawara-cho 54, Kyoto, 606-8507, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Honda
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Hishizawa
authors.forename: Tatsuki R
authors.initials: TR
authors.lastname: Kataoka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Ohmori
authors.forename: Akifumi
authors.initials: A
authors.lastname: Takaori-Kondo
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Miyachi
authors.forename: Kenji
authors.initials: K
authors.lastname: Kabashima
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D018570:Risk Assessment; D013262:Stevens-Johnson Syndrome / Q000209:etiology* / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000187:drug effects*; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D000305:Adrenal Cortex Hormones; D061067:Antibodies, Monoclonal, Humanized; C549035:mogamulizumab